Patient Power

Patient Power® is offered by Patient Power, LLC, which is headquartered in Seattle but has team members from various parts of the globe. The company was established by health communication innovators Andrew and Esther Schorr, who also started HealthTalk.com, a well-known platform that supports those dealing with chronic illnesses and cancer. Patient Power® focuses on empowering cancer patients, survivors, and their families by providing valuable information to help them access the best treatments and achieve or sustain good health.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#230788

United States

#93392

Health/Health Conditions and Concerns

#221

Traffic sources

Monthly visitors

Articles

Endometriosis vs. Endometrial Cancer: Key Differences

1 week ago | patientpower.info | Lindsay Modglin

Jump ToEndometriosisEndometrial CancerKey DifferencesCausesRisk FactorsSymptomsDiagnosisEndometriosis TreatmentEndometrial Cancer TreatmentCancer RiskSee a DoctorTakeawayEndometriosis and endometrial cancer are two distinct conditions affecting the female reproductive system. Both affect the uterus and pelvic organs, but they differ in terms of causes, symptoms, and treatments.
What is POT1 Tumor Predisposition Syndrome in CLL?

1 week ago | patientpower.info | Lindsay Modglin

POT1 tumor predisposition syndrome (POT1-TPDS) is a rare hereditary condition that significantly increases your risk for certain cancers, including chronic lymphocytic leukemia (CLL). Recent research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting offers valuable insights into the other types of cancer people with POT1-TPDS may be most at risk for. What Is POT1-TPDS?
A Safer Option for Some with HER2+ Breast Cancer

1 week ago | patientpower.info | Hailey Hudson

If you’re undergoing treatment for breast cancer, the idea of doing less treatment might seem terrifying. But for some patients with breast cancer, new research is suggesting that doing less might be not only safe, but better. De-escalation is a treatment approach that aims to give patients less treatment, and it was a major focus at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Nodular Sclerosis Hodgkin Lymphoma (NSHL): An Overview

2 weeks ago | patientpower.info | Lindsay Modglin

Jump ToWhat It IsSymptomsRisk FactorsDiagnosisStagingTreatmentChemo Side EffectsPrognosisTakeawayNodular sclerosis Hodgkin lymphoma (NSHL) is the most common type of classical Hodgkin lymphoma (cHL). It accounts for around 70% of cHL cases, according to the Leukemia and Lymphoma Society. The condition primarily affects teens and young adults, with the average age at diagnosis being 28 years old. What It IsWhat is Nodular Sclerosis Hodgkin Lymphoma?
How AI Could Help You Get a More Accurate HER2 Breast Cancer Diagnosis

2 weeks ago | patientpower.info | Hailey Hudson

GettyImages/FatCameraCould artificial intelligence play a role in helping diagnose and categorize cases of HER2 breast cancer? HER2 (human epidermal growth factor receptor 2) is a protein that can affect how breast cancer cells grow and respond to treatment. Accurate diagnosis of HER2 status is critical, as it directly influences treatment decisions and can significantly improve patient outcomes through targeted therapies.
The Heart of CLL: What Are We Learning About Hypertension and Cardiac Safety?

2 weeks ago | patientpower.info | Lindsay Modglin

If you're living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), you've likely heard about Bruton tyrosine kinase inhibitors (BTK inhibitors). These oral medications have transformed treatment for blood cancers. But like many cancer treatments, they come with their own set of challenges. Recent research and data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting shed light on the cardiovascular side effects of different BTK inhibitors.
Light Chain Myeloma: Symptoms, Diagnosis & Treatment Options

3 weeks ago | patientpower.info | Lindsay Modglin

Jump ToLight Chain and Heavy ChainRisk FactorsSymptomsDiagnosisTreatmentOutlookTakeawayLight chain myeloma, also called Bence Jones myeloma, is a rare and aggressive subtype of multiple myeloma. Multiple myeloma is a cancer affecting cells in the bone marrow called plasma cells. The light chain is one component of a larger protein molecule called an immunoglobulin, which plasma cells make.
Cancer Deaths from Alcohol Have Doubled: Know the Hidden Risk and How to Protect Yourself

3 weeks ago | patientpower.info | Marcia Frellick

Cancer deaths caused by heavy alcohol use doubled in the U.S. over the past three decades, according to data presented May 31 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10519). The numbers are highest among men and people age 55 and older. Alcohol’s link to cancer is much less well-known than smoking’s connection to cancer, but alcohol consumption is now the third leading preventable cause of cancer in the U.S., after tobacco use and obesity.
Targeted Therapy for Lung Cancer: How It Works

3 weeks ago | patientpower.info | Lindsay Modglin

Jump ToHow It WorksCommon TargetsAdvantagesLimitationsTakeawayTargeted therapies are treatments that specifically target a genetic mutation found in tumor cells through biopsy analysis or genetic testing, said Nilesh Vora, MD, board-certified hematologist and medical oncologist, and medical director of the MemorialCare Todd Cancer Institute at Long Beach Medical Center in Long Beach, California.
Astrocytoma Survival Rate: Prognosis & Key Factors

1 month ago | patientpower.info | Lindsay Modglin

Jump ToSurvival Rates by GradeKey FactorsPersonalized MedicineTakeawayGliomas are a type of primary brain tumor that originate from a type of brain cell called glial cells. There are several types of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas. "Gliomas are relatively uncommon," said Shawn Zimberg, MD, radiation oncologist and Medical Director of the Advanced Radiation Centers of New York.